Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLIGOPELVIS: Salvage Radiotherapy and Hormonotherapy in Oligometastatic Prostate Cancer
NCT02274779Phase 2Completed
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Aug 2014
- Primary completion
- Jul 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of leuprolide in prostate cancer (PCa), sponsored by Institut Cancérologique de l'Ouest. Primary endpoint: Relapse-Free Survival at 2 years. Started Aug 2014; status: completed.
02
Drugs
leuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02274779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02274779.